Trials / Active Not Recruiting
Active Not RecruitingNCT02446444
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 802 (actual)
- Sponsor
- University of Sydney · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at high risk of recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | |
| DRUG | Conventional NSAA | |
| DRUG | LHRHA | |
| RADIATION | External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2025-06-01
- Completion
- 2026-03-01
- First posted
- 2015-05-18
- Last updated
- 2025-05-30
Locations
69 sites across 9 countries: United States, Australia, Austria, Belgium, Ireland, New Zealand, Slovenia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02446444. Inclusion in this directory is not an endorsement.